Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study
, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 34, 34, 5, 6, 78, 9
Abstract
Background: Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI.
Methods: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.
Results: Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442–59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).
Conclusions: Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.
Keywords: aortic stenosisintestinal metabolitesindoxyl sulfatetranscatheter aortic valve implantationtrimethylamine-N-oxide
References
- Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011; 8(3): 162–172.
- Bonow RO, Greenland P. Population-wide trends in aortic stenosis incidence and outcomes. Circulation. 2015; 131(11): 969–971.
- Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group, ESC/EACTS Scientific Document Group, ESC/EACTS Scientific Document Group, ESC/EACTS Scientific Document Group, ESC/EACTS Scientific Document Group, ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2021; 60(4): 727–800.
- Shimamura J, Takemoto S, Fukuhara S, et al. Long-term outcomes after transcatheter aortic valve replacement: Meta-analysis of Kaplan-Meier-derived data. Catheter Cardiovasc Interv. 2023; 102(7): 1291–1300.
- Gebrayel P, Nicco C, Al Khodor S, et al. Microbiota medicine: towards clinical revolution. J Transl Med. 2022; 20(1): 111.
- Nowiński A, Ufnal M. Gut bacteria-derived molecules as mediators and markers in cardiovascular diseases. The role of the gut-blood barrier. Kardiol Pol. 2018; 76(2): 320–327.
- Tomasova L, Grman M, Ondrias K, et al. The impact of gut microbiota metabolites on cellular bioenergetics and cardiometabolic health. Nutr Metab (Lond). 2021; 18(1): 72.
- Nowiński A, Ufnal M. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases? Nutrition. 2018; 46: 7–12.
- Huć T, Nowinski A, Drapala A, et al. Indole and indoxyl sulfate, gut bacteria metabolites of tryptophan, change arterial blood pressure via peripheral and central mechanisms in rats. Pharmacol Res. 2018; 130: 172–179.
- Ufnal M, Zadlo A, Ostaszewski R. TMAO: A small molecule of great expectations. Nutrition. 2015; 31(11-12): 1317–1323.
- Hung SC, Kuo KL, Wu CC, et al. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. J Am Heart Assoc. 2017; 6(2).
- Gąsecka A, Fidali O, Kłębukowska A, et al. Plasma concentration of TMAO is an independent predictor of adverse outcomes in patients after acute myocardial infarction. Postepy Kardiol Interwencyjnej. 2023; 19(1): 31–39.
- Kocyigit D, Tokgozoglu L, Gurses KM, et al. Association of dietary and gut microbiota-related metabolites with calcific aortic stenosis. Acta Cardiol. 2021; 76(5): 544–552.
- Baratchi S, Zaldivia MTK, Wallert M, et al. Transcatheter Aortic Valve Implantation Represents an Anti-Inflammatory Therapy Via Reduction of Shear Stress-Induced, Piezo-1-Mediated Monocyte Activation. Circulation. 2020; 142(11): 1092–1105.
- Wilimski R, Budzianowski J, Łomiak M, et al. Extracellular Vesicles to Predict Outcomes After Transcatheter Aortic Valve Implantation - a Prospective, Multicenter Cohort Study. J Cardiovasc Transl Res. 2024; 17(5): 992–1003.
- Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
- Guo Y, Xu S, Zhan H, et al. Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome. J Clin Med. 2023; 12(2).
- Carità P, Coppola G, Novo G, et al. Aortic stenosis: insights on pathogenesis and clinical implications. J Geriatr Cardiol. 2016; 13(6): 489–498.
- Fülöp P, Dvorožňáková M, Vachalcová M, et al. [Gut microbiome in heart failure and aortic stenosis]. Vnitr Lek. 2022; 68(E-2): 4–10.
- Janeiro MH, Ramírez MJ, Milagro FI, et al. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. 2018; 10(10).
- Gąsecka A, Rzepa Ł, Konwerski M, et al. Trimethylamine-N-oxide (TMAO) versus echocardiographic, biochemical and histopathological indices of heart failure in patients with severe aortic stenosis: Rationale and design of the prospective, observational TASTE study. Cardiol J. 2022; 29(4): 691–697.
- Thomas MS, Fernandez ML. Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease. Curr Atheroscler Rep. 2021; 23(4): 12.
- Zhu W, Wang Z, Tang WH, et al. Gut Microbe-Generated Trimethylamine -Oxide From Dietary Choline Is Prothrombotic in Subjects. Circulation. 2017; 135(17): 1671–1673.
- Imazu M, Fukuda H, Kanzaki H, et al. Plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure. Sci Rep. 2020; 10(1): 16528.
- Vavilis G, Bäck M, Occhino G, et al. Kidney Dysfunction and the Risk of Developing Aortic Stenosis. J Am Coll Cardiol. 2019; 73(3): 305–314.
- Candellier A, Issa N, Grissi M, et al. Stop-As Investigators. Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve. J Mol Cell Cardiol. 2023; 179: 18–29.
- Delgado-Marin M, Sánchez-Esteban S, Cook-Calvete A, et al. Indoxyl Sulfate-Induced Valve Endothelial Cell Endothelial-to-Mesenchymal Transition and Calcification in an Integrin-Linked Kinase-Dependent Manner. Cells. 2024; 13(6).
- Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J. 2010; 31(14): 1771–1779.
- Yang Ke, Du C, Wang X, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood. 2017; 129(19): 2667–2679.
- Shimazu S, Hirashiki A, Okumura T, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J. 2013; 77(2): 390–396.
- Watanabe I, Tatebe J, Fujii T, et al. Prognostic Utility of Indoxyl Sulfate for Patients with Acute Coronary Syndrome. J Atheroscler Thromb. 2019; 26(1): 64–71.
